A thousand small delays and opportunities for error can snowball over the years of a complex biotherapeutic drug development program. They add up to lost time and increased risk in an endeavor that has little tolerance for either. It doesn’t have to be this way.
To get the most out of recent innovations in biopharma development and QC such as multi-attribute monitoring, it’s time to better connect the systems that manage biopharma data. This series explores the what, the why, and the how of better biopharma data.
Q&A from webinar on using targeted 2D LC (RP-RP) for effective impurity analysis to address peak coelutions The Waters pharmacuetical team recently hosted a webinar discussion how two-dimentional LC can offer a solution to analyze… Read more >
If data can throw your biotherapeutic development program into chaos, it can also help move you forward. Let’s see how.
The improvements in LC-MS technology under GxP compliant-ready informatics for biopharmaceutical analysis has prepared the industry to expand the role of MS technologies beyond product characterization toward monitoring product and process quality attributes.
From oligonucleotides and peptides to messenger RNA and CRISPR, ’tides are enjoying their time in the sun A year ago we wrote how oligonucleotide therapeutic development, which had seen a huge wave of investment in… Read more >
“One of the important reasons that we use Waters LC-MS instruments is that beyond the quality of the products, Waters delivers a high degree of technical training. This provides us with the knowledge and confidence that we can solve our complex research questions.” comments Triskelion’s Richard Bas.
“If You Build it, He Will Come” Urged on by a voice no one else could hear, Ray Kinsella, played by Kevin Costner in the movie Field of Dreams, cleared a few acres of corn… Read more >
In biotherapeutics, the state of glycosylation has a direct and pronounced effect of the structure, stability, serum half-life, immunogeneicity and bioactivity of the molecule, and constitutes a critical quality attribute (CQA). In our study, characterizing and comparing the glycosylation profile of infliximab began by examining the glycosylation profiles from intact and reduced subunit mass data.
Advancements in High-Resolution Analytics for Characterization of Innovator and Biosimilar Therapeutics Part 2: Peptide Analysis of Infliximab